Jubilant Ingrevia Limited (NSE:JUBLINGREA)
India · Delayed Price · Currency is INR | Market Cap | 107.29B -7.3% |
| Revenue (ttm) | 46.50B +11.0% |
| Net Income | 3.09B +11.2% |
| EPS | 19.44 +11.0% |
| Shares Out | 157.72M |
| PE Ratio | 35.00 |
| Forward PE | 25.54 |
| Dividend | 5.00 (0.72%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 78,743 |
| Open | 680.70 |
| Previous Close | 680.30 |
| Day's Range | 673.00 - 684.95 |
| 52-Week Range | 537.30 - 795.00 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 967.17 (+43.18%) |
| Earnings Date | Oct 27, 2026 |
About Jubilant Ingrevia
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments, Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health s... [Read more]
Financial Performance
In fiscal year 2026, Jubilant Ingrevia's revenue was 43.88 billion, an increase of 5.04% compared to the previous year's 41.78 billion. Earnings were 2.78 billion, an increase of 10.64%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for JUBLINGREA stock is "Strong Buy." The 12-month stock price target is ₹967.17, which is an increase of 43.18% from the latest price.
News
Jubilant Ingrevia Transcript: Q1 26/27
Q1 FY27 saw revenue up 25% and EBITDA up 36% year-over-year, driven by strong growth in specialty chemicals, nutrition, and chemical intermediates. The company maintained its FY27 EBITDA guidance and expects sequential improvement, with a robust CDMO pipeline and continued operational excellence.
Jubilant Ingrevia Quarterly report: Q1 2027
Jubilant Ingrevia has published its Q1 2027 quarterly earnings report on July 23, 2026.
Jubilant Ingrevia Slides: Q1 2027
Jubilant Ingrevia has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 23, 2026.
Jubilant Ingrevia Transcript: Q4 25/26
Q4 FY 2026 saw record revenue and EBITDA, driven by strong specialty chemicals and nutrition growth, with robust outlook for FY 2027 and continued investment in capacity. Net debt and working capital improved, and the company remains confident in achieving 20% EBITDA growth.
Jubilant Ingrevia Quarterly report: Q4 2026
Jubilant Ingrevia has published its Q4 2026 quarterly earnings report on May 26, 2026.
Jubilant Ingrevia Slides: Q4 2026
Jubilant Ingrevia has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 26, 2026.
Jubilant Ingrevia Annual report: Q4 2026
Jubilant Ingrevia has published its Q4 2026 annual report on May 26, 2026.
Jubilant Ingrevia reports 12% revenue growth in Q4 FY26 with ₹1,179 crore
Jubilant Ingrevia Limited has announced a robust financial performance for the fourth quarter of the fiscal year 2026, with total revenue reaching ₹1,179 crore, marking a 12% year-on-year increase. Th...
Jubilant Ingrevia grants 3,43,569 stock options under employee plan
Jubilant Ingrevia has announced the grant of 3,43,569 stock options to eligible employees under its Employees Stock Option Plan 2021. This decision was approved by the Nomination, Remuneration and Com...
Jubilant Ingrevia completes acquisition of 100% stake in Remidex Pharma
Jubilant Ingrevia has successfully acquired a 100% equity stake in Remidex Pharma Private Limited. This acquisition was completed as per the Share Purchase Agreement previously announced by the compan...
Jubilant Ingrevia's subsidiary begins commercial production at Bharuch site
Jubilant Ingrevia Limited has announced that its wholly owned subsidiary, Jubilant Agro Sciences Limited, has commenced commercial production of agro intermediates at its Bharuch site. This developmen...
Jubilant Ingrevia to acquire Remidex Pharma for Rs 16.5 crore
Jubilant Ingrevia has announced its acquisition of Remidex Pharma Private Limited for ₹16.5 crore, marking a strategic expansion into the human nutrition sector. Remidex, based in Bangalore and establ...
Brokerage radar, March 10: Dixon Technologies, Meesho, Jubilant Ingrevia, Amber Enterprises among top stocks to watch today
Brokerage firms released several key stock recommendations and sector outlooks on March 10 (IST), covering companies across electronics manufacturing, insurance, defence, chemicals, and oil marketing....
Jubilant Ingrevia Transcript: Q3 25/26
Specialty chemicals and nutrition segments drove volume and EBITDA growth despite pricing pressures, with strong CDMO pipeline wins and major capacity expansions underway. FTAs and cost initiatives are expected to support margin recovery and market share gains in coming quarters.
Jubilant Ingrevia Quarterly report: Q3 2026
Jubilant Ingrevia has published its Q3 2026 quarterly earnings report on February 5, 2026.
Jubilant Ingrevia Slides: Q3 2026
Jubilant Ingrevia has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 5, 2026.
Top stocks to watch today, October 28: Jubilant Ingrevia, PNB Housing, Indus Tower, Sona BLW, JK Tyre and more
Indian stock markets are expected to remain stock-specific on Tuesday, October 28, with several companies in focus following key announcements,...
Jubilant Ingrevia Transcript: Q2 25/26
Q2 and H1 FY26 saw record revenue and volume growth, led by specialty chemicals and robust CDMO pipeline. Margins improved despite pricing pressures, with strong cost controls and new capacity expansions supporting future growth.
Jubilant Ingrevia Quarterly report: Q2 2026
Jubilant Ingrevia has published its Q2 2026 quarterly earnings report on October 27, 2025.
Jubilant Ingrevia Slides: Q2 2026
Jubilant Ingrevia has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 27, 2025.
Jubilant Ingrevia Q2 Results: Revenue jumps 7.2% YoY to Rs 1,120.7 crore, net profit up 17.8%
Jubilant Ingrevia Limited reported a steady performance in the September quarter of FY26, with both revenue and profit showing year-on-year...
Jubilant Ingrevia Transcript: Q1 25/26
Specialty and Nutrition segments drove strong Q1 FY26 results, with EBITDA up 29% and PAT up 54% year-on-year. Strategic CapEx, cost optimization, and new export opportunities in Europe position the company for continued growth, with a robust pipeline across key markets.
Jubilant Ingrevia Quarterly report: Q1 2026
Jubilant Ingrevia has published its Q1 2026 quarterly earnings report on July 31, 2025.
Jubilant Ingrevia Slides: Q1 2026
Jubilant Ingrevia has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on July 31, 2025.
Jubilant Ingrevia Q1 Results: Revenue flat at Rs 1037 crore, Net Profit surges 54% YoY
Jubilant Ingrevia Limited reported its financial performance for the quarter ended June 30, 2025 (Q1 FY26), showcasing a strong improvement in profitability. Key Highlights: Revenue from Operations: ₹...